New drug pacritinib takes on standard therapy for rare leukemia
Disease control
Recruiting now
This phase 2 trial compares pacritinib to the standard drug hydroxyurea in 66 adults with advanced proliferative chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib improves blood cell counts, reduces spleen size, and controls symptoms better than hydroxyurea…
Phase: PHASE2 • Sponsor: Theradex • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC